| Project/Area Number |
22830038
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Business administration
|
|---|
| Research Institution | Tokai University (2011)
Kyoto University (2010) |
|---|
Principal Investigator |
KAMEOKA Kyoko 東海大学, 政治経済学部, 准教授 (80589614)
|
|---|
| Project Period (FY) |
2010 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥2,444,000 (Direct Cost: ¥1,880,000、Indirect Cost: ¥564,000)
Fiscal Year 2011: ¥1,248,000 (Direct Cost: ¥960,000、Indirect Cost: ¥288,000)
Fiscal Year 2010: ¥1,196,000 (Direct Cost: ¥920,000、Indirect Cost: ¥276,000)
|
|---|
| Keywords | 新製品開発 / ドラッグ・ラグ / 臨床試験 / 標準化 / 外部化 / 業務の切り分け / 医薬品の研究開発 / 研究開発マネジメント / 臨床開発業務の外部化 / 開発業務受託機関（CRO） / 業務の標準化 / 臨床開発 / CRO |
|---|
| Research Abstract |
The research explores what Japanese can do to eliminate the drug lag problem from the perspective of business strategy, especially outsourcing strategy. We interviewed several drug makers in US, UK, Switzerland and Japan. As the result, we found that overseas makers regard clinical development as labor intensive and standardized operations, while Japanese makers take it as critical activities for sales as well as development, making their operations complicated.
|
